Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: A meta-analysis

Abstract

The safety of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) used in hemodialysis (HD) patients was evaluated. Medline, Embase, the Cochrane Library, some databases of clinical trial registries, grey literatures, other reference lists of eligible articles and review articles for the randomized clinical trials (RCTs) on comparison of ACEIs/ARBs or placebo in HD patients were retrieved. RCTs reporting the risk of hyperkalemia by using ACEIs/ARBs in HD patients were selected. Eight articles met the eligibility criteria and were subjected to meta-analysis by using the Cochrane Collaboration’s RevMan 4.2 software package. The results showed that there was no significant difference in hyperkalemia in HD patients between ACEIs or ARBs group and control group (ACEIs vs. control: RD=0.03, 95% CI=−0.13–0.18, Z=0.34, P=0.73; ARBs vs. control: RD=−0.02, 95% CI=−0.07–0.03, Z=0.75, P=0.45). However, there was no significant difference in the serum potassium between ACEIs or ARBs group and control group in HD patients (ACEIs vs. control: WMD=0.10, 95% CI=0.06–0.15, Z=4.64, P<0.00001; ARBs vs. control: WMD=-0.24, 95% CI=−0.37–0.11, Z=3.58, P=0.0003). The use of ACEIs or ARBs could not cause an increased risk of hyperkalemia in HD patients, however the serum potassium could be increased with use of ACEIs in HD patients. Therefore the serum potassium concentration should still be closely monitored when ACEIs are taken during the maintenance HD.

Keywords

angiotensin-converting enzyme inhibitors / angiotensin receptor blockers / hyperkalemia / Meta-analysis

References

[1] CollinsA.J., FoleyR.N., ChaversB., et al.. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis, 2012, 59(1Suppl1): A7, e1-e420

[2] ChangT.I., ShilaneD., BrunelliS.M., et al.. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J, 2011, 162(2): 324-330

[3] LocatelliF., PalmerB.F., KashiharaN., et al.. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Curr Med Res Opin, 2009, 25(12): 2933-2949

[4] K/DOQI clinical. practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis, 2005, 45(4 Suppl 3): S1-S153

[5] HanS.W., WonY.W., YiJ.H., et al.. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance hemodialysis patients. Nephrol Dial Transplant, 2007, 22(4): 1150-1155

[6] GrossP., PistroschF.. Hyperkalaemia: again. Nephrol Dial Transplant, 2004, 19(9): 2163-2166

[7] GarthwaiteE., BhandariS.. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function. Artif Organs, 2009, 33(8): 641-647

[8] PalmerB.F.. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med, 2004, 351(6): 585-592

[9] ChandnaS.M., FarringtonK.. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial, 2004, 17(3): 196-201

[10] KnollG.A., SahgalA., NairR.C., et al.. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med, 2002, 112(2): 110-114

[11] ZannadF., KesslerM., LehertP., et al.. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int, 2006, 70(7): 1318-1324

[12] KhedrE., AbdelwhabS., El-SharkawyM., et al.. Prevalence of hyperkalemia among hemodialysis patients in Egypt. Ren Fail, 2009, 31(10): 891-898

[13] SuzukiH., KannoY., SugaharaS., et al.. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis, 2008, 52(3): 501-506

[14] OttossonP., AttmanP.O., AgrenA.C., et al.. Candesartan cilexetil in haemodialysis patients. Clin Drug Investig, 2003, 23(8): 545-550

[15] TakahashiA., TakaseH., ToriyamaT., et al.. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant, 2006, 21(9): 2507-2512

[16] Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org

[17] NavaneethanS.D., NigwekarS.U., SehgalA.R., et al.. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol, 2009, 4(3): 542-551

[18] AlfieJ., AparicioL.S., WaismanG.D.. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials, 2011, 6(2): 134-146

[19] SadjadiS.A., McmillanJ.I., JaipaulN., et al.. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag, 2009, 5(3): 547-552

[20] SchaeferT.J., WolfordR.W.. Disorders of potassium. Emerg Med Clin North Am, 2005, 23(3): 723-747

[21] SoodM.M., SoodA.R., RichardsonR.. Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia. Mayo Clin Proc, 2007, 82(12): 1553-1561

[22] SuzukiH.. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis. Ther Adv Cardiovasc Dis, 2009, 3(5): 397-405

[23] ChanK.E., IkizlerT.A., GamboaJ.L., et al.. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int, 2011, 80(9): 978-985

[24] FriedrichJ.O., AdhikariN.K., BeyeneJ.. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol, 2007, 7: 5